1. Home
  2. EW vs NTRA Comparison

EW vs NTRA Comparison

Compare EW & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Edwards Lifesciences Corporation

EW

Edwards Lifesciences Corporation

HOLD

Current Price

$90.30

Market Cap

51.3B

Sector

Health Care

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

SELL

Current Price

$402.23

Market Cap

56.7B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
EW
NTRA
Founded
1958
2003
Country
United States
United States
Employees
16000
N/A
Industry
Industrial Specialties
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
51.3B
56.7B
IPO Year
1999
2015

Fundamental Metrics

Financial Performance
Metric
EW
NTRA
Price
$90.30
$402.23
Analyst Decision
Buy
Strong Buy
Analyst Count
30
23
Target Price
$101.39
★ $411.39
AVG Volume (30 Days)
★ 3.1M
1.4M
Earning Date
11-04-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 0.65
EPS
★ 1.07
N/A
Revenue
★ $6,067,600,000.00
$210,939,000.00
Revenue This Year
$11.42
$26.20
Revenue Next Year
$9.91
$20.84
P/E Ratio
$83.43
★ N/A
Revenue Growth
★ 11.55
N/A
52 Week Low
$74.66
$181.00
52 Week High
$96.29
$437.41

Technical Indicators

Market Signals
Indicator
EW
NTRA
Relative Strength Index (RSI) 60.19 56.87
Support Level $82.21 $380.39
Resistance Level $93.43 $437.41
Average True Range (ATR) 2.02 16.45
MACD 0.56 -2.59
Stochastic Oscillator 93.62 58.34

Price Performance

Historical Comparison
EW
NTRA

About EW Edwards Lifesciences Corporation

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: